The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s loss. Read more…
Nature Communications, Published online: 13 May 2025; doi:10.1038/s41467-025-59485-9 Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved body composition through preservation of lean mass and enhanced fat mass loss in obese primates.
Wegovy and Mounjaro have been taking the world by storm for their unprecedented ability to help people shed weight. New studies suggest that the injections stop heart attacks and strokes, not just through weight loss, but also by an anti-inflammatory effect. The same explanation may be behind why they are better than expected at preventing … Read more
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top. Continue Reading Category: Obesity, Illnesses and conditions, Body & Mind Tags: GLP-1 receptor agonists, Obesity, Weight Loss, clinical trials, Weill Cornell Medicine
Scientific Reports, Published online: 13 May 2025; doi:10.1038/s41598-025-99622-4 Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials
This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic eating), “hungry gut” (abnormal satiety), and “slow burn” (decreased metabolic rate). A clinical trial showed that the phenotype-guided approach resulted in significantly greater weight loss and … Read more
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and researchers have struggled to answer a deceptively simple question: Who should be taking them? The medications are highly effective at inducing weight loss, and most Americans are overweight or have obesity. But GLP-1s are also expensive, … Read more
For many people, Ozempic is a game-changer in the fight against obesity. But while the drug is known for its powerful appetite-suppressing effects, some users are reporting dramatic shifts in how food tastes. These Ozempic-driven taste changes can include strong aversions to meat, fried foods, and even formerly favorite dishes—turning once-loved meals into culinary turn-offs. … Read more
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year’s European Congress on Obesity (ECO 2025) suggests.
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.